Source: Lung cancer. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, CARCINOMA BRONCOGÊNICO, IMUNOTERAPIA, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NOSAKI, Kaname et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer, v. 135, p. 188-195, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.lungcan.2019.07.004. Acesso em: 28 ago. 2024.APA
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., Castro Junior, G. de C., Reck, M., et al. (2019). Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung cancer, 135, 188-195. doi:10.1016/j.lungcan.2019.07.004NLM
Nosaki K, Saka H, Hosomi Y, Baas P, Castro Junior G de C, Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [Internet]. Lung cancer. 2019 ; 135 188-195.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1016/j.lungcan.2019.07.004Vancouver
Nosaki K, Saka H, Hosomi Y, Baas P, Castro Junior G de C, Reck M, Wu Y-L, Brahmer JR, Felip E, Sawada T. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [Internet]. Lung cancer. 2019 ; 135 188-195.[citado 2024 ago. 28 ] Available from: https://doi.org/10.1016/j.lungcan.2019.07.004